278 results about "Pulmonary fibroses" patented technology

The present invention relates to a compound represented by formula (I-0):wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous disease (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells may be size restricted such as being greater than about 60 nm so that they selectively extravasate at sites of angiogenesis (e.g. tumor) and do not pass through normal vasculature or enter non-tumor bearing tissue. In this way, angiogenic sites can be both detected and treated. In another embodiment, nanocells are tailored for various treatment methods, including the treatment of brain cancer, asthma, Grave's Disease, Cystic Fibrosis, and Pulmonary Fibrosis.

The invention relates to compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention discloses a Chinese medicinal composition for treating pulmonary fibrosis and its application. The Chinese medicinal composition consists of the following components by weight: 3.6-4 parts of Bletilla striata, 0.9-1.2 parts of Galla Chinensis, 1-1.2 parts of Bombyx Batryticatus, 4-4.5 parts of rhizoma atractylodis macrocephalae, 4-5 parts of Adenophora elata, 4-4.5 parts of Radix Stemonae, 1-1.2 parts of platycodon grandiflorum, and 7-8 parts of codonopsis pilosula. Research shows that the aqueous extract of the Chinese medicinal composition provided in the invention has an obvious inhibiting effect on a pulmonary fibrosis animal model TGF beta, and the composition can be used for preparing anti-pulmonary fibrosis drugs. In the invention, new application and treatment mechanism of the Chinese medicinal composition are developed. The Chinese medicinal composition is in favor of studying the pulmonary fibrosis mechanism and treatment drugs, and provides an experimental foundation for new drugs treating pulmonary fibrosis.

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Some embodiments of the invention include methods for treating an animal for fibrosis comprising one or more administrations of one or more compositions comprising one or more opioid receptor inhibitors. Other embodiments of the invention further include other fibrosis treatments. Still other embodiments of the invention include methods for treating a human for idiopathic pulmonary fibrosis, comprising administering one or more compositions comprising naltrexone and optionally administering one or more compositions comprising pirfenidone, nintedanib, or both. Additional embodiments of the invention are also discussed herein.

The invention relates to the field of medicine synthesis, and discloses a GIP / GLP-1 analogue. The GIP / GLP-1 analogue is used for preparing a pharmaceutical composition for treating diseases, and the pharmaceutical composition is used for preparing a medicine for treating at least one of the following diseases: type-II diabetes, impaired glucose tolerance, type-I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive disorder, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory intestinal syndrome and / or dyspepsia orgastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

<heading lvl="1">SUMMARY OF THE INVENTION < / heading> The use of gene therapy for the treatment of different kinds of fibrosis in human beings is disclosed. The purpose is the use of "therapeutic2 genes specifically directed to target organs to revert and / or prevent the development of the fibrosis process. The potential application of gene therapy to patients with fibrosis and / or cirrhosis will depend to a large extent on the successful delivery of genes which encode for therapeutic proteins to livers with severe fibrosis and that these genes which encode for proteins human MMP-8 active and latent, MMP-1, MMP-2, MMP-9 and MMP-13; human uPA wild type and / or modified (or its truncated version), the truncated receptor for TGF-beta type II and Smad-7 can be directed by adenovirus and / or other recombinant vectors that cannot transduce (infect) others organs. The recombinant adenoviruses (AdR) are vectors highly efficient for the transduction of therapeutic genes to diverse target cells. We have proved that they can carry genes to cirrhotic livers. The delivery of therapeutic genes through such adenoviral vectors and other recombinant vectors could also be performed using cationic and anionic liposomes (DOTMA). Therefore, we propose the use of this patent to be applied in the same manner to: Renal fibrosis Pulmonary fibrosis Hypertrophic and keloid scars (skin fibrosis), and Other kinds of fibrosis.

This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and / or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring / wound healing abnormalities, post operative adhesions, and reactive fibrosis. The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat fibrotic conditions.

The invention discloses an ethanesulfonic acid nintedanib dispersible tablet used for treating idiopathic pulmonary fibrosis (IPF). Ethanesulfonic acid nintedanib serves as the raw material, auxiliary materials are added, and the ethanesulfonic acid nintedanib dispersible tablet is prepared. The ethanesulfonic acid nintedanib dispersible tablet is rapid to disintegrate and absorb, high in bioavailability, convenient to take, less in intestinal tract residue, few in side effect and sweet in taste and has fragrance, medicine taking compliance of patients is particularly easy to improve, the taste of the preparation is improved, the sticking phenomenon cannot occur in the tabletting process, and industrial production is promoted.

The invention provides application of pazopanib hydrochloride to preparing medicines for treating pulmonary fibrosis diseases, and further provides a medicine composition. The medicine composition contains the pazopanib hydrochloride, excipients and pharmaceutically acceptable salt, ester and hydrates of the pazopanib hydrochloride or compositions of the salt, the ester and the hydrates. The application and the medicine composition have the advantages that excellent effects can be realized by the pazopanib hydrochloride for pulmonary fibrosis, adverse reaction can be prevented, bleomycin-induced pulmonary fibrosis in mice can be relieved, and the medicine composition has an excellent application prospect for treating, relieving and improving the pulmonary fibrosis diseases.

The invention provides a pulmonary fibrosis detection and severity evaluation method based on deep learning, and the method comprises the steps: S1, preprocessing chest CT sequence images of a plurality of pulmonary fibrosis patients, and obtaining a plurality of first CT images; S2, extracting and labeling a plurality of first CT images to generate a training set and a verification set; S3, pre-training a first deep convolutional neural network model and a second deep convolutional neural network model through the training set and the verification set; S4, inputting the CT image sequence of the patient to be detected into the trained first and second deep convolutional neural network models, and identifying a lung region and a pulmonary fibrosis focus region contained in each CT image inthe CT image sequence of the patient; calculating to obtain the proportion of the pulmonary fibrosis focus of the patient in the lung; S5, marking pulmonary fibrosis staging based on the proportion; and S6, grading the pulmonary fibrosis severity of the patient based on the detection result of the physiological parameters. The invention further comprises a pulmonary fibrosis detection and severityevaluation system based on deep learning.

The purpose of the present invention is to provide a novel treatment agent for pulmonary fibrosis for which there is currently no effective drug therapy established. The present invention is a pulmonary fibrosis treatment agent containing mesenchymal stem cells. The pulmonary fibrosis is preferably usual interstitial pneumonia (UIP) or idiopathic pulmonary fibrosis (IPF). Also, the mesenchymal stem cells are preferably derived from adipose tissue or are allogeneic.

This invention concerns adamantanamines (e.g. memantine, amantadine, and rimantadine) and neramexane salts of thiomolybdic and thiotungstic acids, including their preparation and pharmaceutical compositions, as dual acting drugs. These salts are used to treat or potentially arrest the neurodegenerative pathophysiology, clinical signs and symptoms of dementia of the Alzheimer's type, Parkinson's, Huntington's, AIDS-related dementia and Schizophrenia and its cognitive deficits. Additional uses of these derivatives include antiviral activity. The novel compositions of the present invention appear particularly useful in enhancing the therapeutic benefits of copper-sequestering tetrathiomolybdates in treating elevated copper-induced toxicities in neurologically presenting Wilson's disease, and in treating diseases of the inflammatory etiology and abnormal copper biochemistry, such as tumor angiogenesis, liver cirrhosis, hepatitis, pulmonary fibrosis and other fibrotic diseases, cardiovascular disease, cerebral ischemia, renal anemia, rheumatoid arthritis, diabetes, obesity, gastrointestinal disorders, and eye diseases such as glaucoma, proliferative diabetic retinopathy, and age related macular degeneration. These compounds have excellent stability and aqueous solubility for good oral bioavailability.